Completed PHASE3 INTERVENTIONAL 1-arm NCT05320575

Zanubrutinib for HLH

Zanubrutinib Monotherapy in Patients With Hemophagocytic Lymphohistiocytosis

Sponsor: Beijing Friendship Hospital

Conditions HLH

Updated 4 times since 2022 Last updated: Apr 10, 2024 Started: Feb 1, 2022 Primary completion: Aug 1, 2023 Completion: Aug 1, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates HLH and is currently completed. Beijing Friendship Hospital leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
May 2024 — Jul 2024 [monthly]

Completed PHASE3

Status: Recruiting → Completed
May 2022 — May 2024 [monthly]

Recruiting PHASE3

First recorded

Feb 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing Friendship Hospital

Data source: Beijing Friendship Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China